Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
Original Article: NICE rejects rare eye disease drug
NEXT ARTICLE